GLP-1 Medications in Type 1 Diabetes: New Expert Consensus Explained
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the treatment of obesity and type 2 diabetes. But what benefits might these medications offer people living with type 1 diabetes (T1D)?
Although GLP-1 and GLP-1/GIP medications are not FDA-approved for type 1 diabetes, off-label use has grown as studies and real-world experience show potential benefits, including weight loss, lower insulin requirements, improved glucose management, and better quality of life. Until recently, however, clinicians had little guidance on how to use these medications safely in people with T1D.
A new international consensus report aims to change that. In this article, we’ll review the latest recommendations, summarize the evidence, and explain what people with type 1 diabetes and their healthcare teams need to know.
At a Glance
- GLP-1 medications are not FDA-approved for type 1 diabetes, but off-label use is increasing.
- A new international consensus provides guidance for the safe use of GLP-1 medications in people with type 1 diabetes.
- Successful treatment requires careful dose titration, patient education, and ongoing monitoring.
- Insulin should never be discontinued in people with type 1 diabetes, even if insulin needs decrease.
Why Aren't GLP-1 Medications Approved for Type 1 Diabetes?
This is one of the most common questions people with type 1 diabetes ask. The short answer is that GLP-1 medications have not yet received FDA approval for type 1 diabetes, not because they don’t work, but because more research is still needed.
Why Has FDA Approval Taken Longer?
The truth is that most studies of GLP-1 medications in people with type 1 diabetes have been relatively small, and much of the available evidence comes from real-world experience and observational studies.
Larger randomized clinical trials are now underway to better understand the long-term safety and effectiveness of these medications. Researchers are also evaluating important safety considerations, including how to safely adjust insulin doses and minimize the risk of diabetic ketoacidosis (DKA).
The new international consensus recognizes that many HCPs are already prescribing GLP-1 medications off-label for people with type 1 diabetes.
As a result, the report focuses on helping clinicians use these medications safely while additional research continues.
What Makes This Consensus Statement Different?
Rather than debating whether GLP-1 medications should be used in people with type 1 diabetes, the consensus focuses on how to use them safely in appropriate patients who are already receiving them off-label.
The recommendations were developed and endorsed by several leading international diabetes organizations, including:
This broad international support adds credibility to the recommendations and provides clinicians with practical guidance while additional research continues.
The Biggest Takeaways for Clinicians
The new international consensus provides practical recommendations to help clinicians safely incorporate GLP-1 medications into the care of selected people with type 1 diabetes. Here are the most important clinical pearls and implementation strategies from the report.
Identifying Appropriate Candidates for GLP-1 Therapy
The international consensus suggests that GLP-1 medications may be considered for selected adults with type 1 diabetes, particularly those who have:
- Overweight or obesity
- Persistent hyperglycemia despite optimized insulin therapy
- Established cardiovascular disease, chronic kidney disease, or other conditions where these medications may provide additional benefit
Importantly, these medications are not recommended for routine use in everyone with type 1 diabetes. Treatment decisions should be individualized based on each person’s health goals, medical history, and potential risks and benefits.
Start Low and Increase the Dose Slowly
One of the strongest messages in the consensus report is to start with the lowest dose and increase gradually to improve tolerability.
The authors recommend:
- Starting with the lowest available dose.
- Increasing the dose slowly based on individual response and side effects.
- Extending dose increases to every 2 to 3 months, rather than monthly, for some people.
A slower titration schedule can help reduce common gastrointestinal side effects, such as nausea, vomiting, and diarrhea, making treatment more comfortable and improving the likelihood of long-term success.
Education Is Just as Important as the Prescription
One of the strongest recommendations in the consensus report is that patient education is critical for the safe use of GLP-1 medications in people with type 1 diabetes.
Before starting treatment, patients should receive education on:
- Adjusting insulin doses safely
- Recognizing and treating hypoglycemia
- Preventing and recognizing ketosis and diabetic ketoacidosis (DKA)
- Sick-day management
- Staying well hydrated
- Managing common gastrointestinal side effects
The authors emphasize that GLP-1 medications should not be prescribed without comprehensive education and ongoing follow-up.Â
Continuous Glucose Monitoring Is Essential
The consensus treats CGM as an essential safety tool, not just a glucose monitoring device. It recommends using CGM to:
- Guide insulin dose reductions
- Detect hypoglycemia and hyperglycemia early
- Maintain adequate insulin to reduce the risk of ketosis
- Monitor treatment response using Time in Range (TIR), rather than relying on A1C alone
Never Discontinue Insulin
If clinicians remember only one recommendation from this consensus report, it should be this: never discontinue insulin in people with type 1 diabetes.
Although GLP-1 medications often reduce insulin requirements, insulin therapy remains essential. Clinicians should proactively adjust insulin doses throughout treatment while maintaining adequate basal insulin to minimize the risk of DKA.
A Turning Point for GLP-1 Therapy in Type 1 Diabetes
For me, the biggest takeaway from this consensus report is that the conversation has shifted. Rather than debating whether GLP-1 therapy can benefit people with type 1 diabetes, we’re now asking how to use these medications safely and effectively in appropriate patients.
I hope this consensus helps move the field toward broader clinical adoption, improved insurance coverage, and more thoughtful discussions about where GLP-1 therapy fits within the overall management of type 1 diabetes.
Ready to Strengthen Diabetes Care and Education in Your Practice?
Are you looking to build, refine, or expand diabetes care and education services within your practice? I provide flexible, consultative support designed to meet the needs of busy clinics and healthcare organizations.
Diabetes care and education is central to my work. My approach focuses on translating current evidence and standards of care into clear, practical strategies that support sustainable behavior change and informed decision-making.
Let me help you develop patient-centered diabetes care and education that integrates seamlessly into clinical care. Book a discovery call to explore how we might work together.
In short, yes. Although GLP-1 and GLP-1/GIP medications are not currently FDA-approved for people with type 1 diabetes, some healthcare providers prescribe them “off-label,” especially for people who also have overweight or obesity.
A new international consensus report offers practical guidance to help clinicians use these medications safely and appropriately in selected individuals.
The main reason is that there haven’t yet been enough large, high-quality clinical trials to meet the standards required for FDA approval.
While smaller studies and real-world experience have shown promising improvements in weight, blood sugar, and insulin needs, larger studies are still underway to better understand the long-term benefits and safety of these medications.
The report focuses mainly on semaglutide and tirzepatide because these are the medications most commonly used today and have the strongest emerging evidence in people living with type 1 diabetes.
Absolutely. People with type 1 diabetes should never stop taking insulin, even if their blood sugar improves significantly. These medications often reduce the amount of insulin needed, especially at mealtimes, but insulin is still essential for survival.
Stopping insulin completely can quickly lead to diabetic ketoacidosis (DKA), a serious and potentially life-threatening complication.
Discover more from Sarah Hormachea
Subscribe to get the latest posts sent to your email.
